Duloxetine on Bone Metabolism

The Effect of Duloxetine on Bone Metabolism

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05550506

Enrollment

102

Registered

2022-09-22

Start date

2022-07-27

Completion date

2022-12-25

Last updated

2022-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain, Fibromyalgia

Keywords

duloxetine, chronic pain, fibromyalgia, bone metabolism

Brief summary

The aim of the study was to determine the effect of duloxetine as monotherapy on biochemical markers and bone mineral density.

Detailed description

51 patients diagnosed with chronic pain or fibromyalgia syndrome who were using duloxetine for at least 3 months and age and sex matched 51 healthy individuals were recruited for this cross-sectional study. Bone mineral density of both groups were measured by dual energy x ray absorbsiometry(DXA), bone biochemical markers, serum calcium, and vitamin D levels were investigated.

Interventions

DRUGDuloxetine

Patients who use duloxetine for chronic pain or fibromyalgia

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* \>18 years or \<50 years * patients using duloxetine for at least 3 months due to chronic pain or fibromyalgia

Exclusion criteria

* postmenopausal women * clinical conditions which cause secondary osteoporosis * patients using medication that cause secondary osteoporosis * pregnancy and malignity

Design outcomes

Primary

Measure	Time frame	Description
DXA	3 months	Bone mineral densitomtry
CTX	3 months	C-terminal telopeptide
OC	3 months	Osteocalcin
25-OH VITD3	3 months	25-hydroxyvitamin D3

Countries

Turkey (Türkiye)

Contacts

Primary ContactBayram Kelle, Assoc. Prof.

bayramkelle@yahoo.com903223386060-3161

Backup ContactBayram Kelle, Assoc. Prof